Ignite Creation Date:
2024-05-05 @ 6:50 PM
Last Modification Date:
2024-10-26 @ 9:37 AM
Study NCT ID:
NCT00550771
Status:
COMPLETED
Last Update Posted:
2017-06-07
First Post:
2007-10-29
Brief Title:
Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer Study P05048
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Breast Neoplasm |
Keywords: